Bet-in-23 (Compound 23) is a BD2-selective BET inhibitor with an IC 50 of 2.9 nM. BET-IN-23 has anticancer activity and can significantly inhibit the proliferation of acute myeloid leukemia (AML) cell lines by inducing G0/G1 arrest and apoptosis in vitro.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetic Reader Domain
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.